Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alicia Leon-Castillo

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Pathology|January 19, 2018
The rise of a novel classification system for endometrial carcinoma; integration of molecular subclassesJessica McAlpine, Alicia Leon-Castillo, Tjalling Bosse
Histopathology|April 9, 2021
Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancerLisa Vermij, Naveena Singh, Alicia Leon-Castillo, et al.
Acta Obstetricia Et Gynecologica Scandinavica|July 30, 2024
Do we more often opt for conservative management of ovarian tumors after changing the Dutch national guideline on enlarged ovaries? A nationwide cohort studyEsther Lems, Anna H Koch, Sam Armbrust, et al.
Journal of Cutaneous Pathology|May 31, 2017
Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma seriesAlicia Leon-Castillo, John S A Chrisinger, Gauri Panse, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 28, 2025
Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER StatusPatrick Thaddeus Timmermans, Alicia Leon-Castillo, Claire Kramer, et al.
Cancers|December 30, 2020
HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical OutcomesLisa Vermij, Nanda Horeweg, Alicia Leon-Castillo, et al.
Gynecologic Oncology|January 26, 2022
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatmentAlicia Leon-Castillo, Nanda Horeweg, Elke E M Peters, et al.
JCO Global Oncology|May 25, 2023
<i>QPOLE</i>: A Quick, Simple, and Cheap Alternative for <i>POLE</i> Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain ReactionAnne Sophie V M Van den Heerik, Natalja T Ter Haar, Lisa Vermij, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Pathology|January 19, 2018
The rise of a novel classification system for endometrial carcinoma; integration of molecular subclassesJessica McAlpine, Alicia Leon-Castillo, Tjalling Bosse
Histopathology|April 9, 2021
Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancerLisa Vermij, Naveena Singh, Alicia Leon-Castillo, et al.
Acta Obstetricia Et Gynecologica Scandinavica|July 30, 2024
Do we more often opt for conservative management of ovarian tumors after changing the Dutch national guideline on enlarged ovaries? A nationwide cohort studyEsther Lems, Anna H Koch, Sam Armbrust, et al.
Journal of Cutaneous Pathology|May 31, 2017
Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma seriesAlicia Leon-Castillo, John S A Chrisinger, Gauri Panse, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 28, 2025
Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER StatusPatrick Thaddeus Timmermans, Alicia Leon-Castillo, Claire Kramer, et al.
Cancers|December 30, 2020
HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical OutcomesLisa Vermij, Nanda Horeweg, Alicia Leon-Castillo, et al.
Gynecologic Oncology|January 26, 2022
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatmentAlicia Leon-Castillo, Nanda Horeweg, Elke E M Peters, et al.
JCO Global Oncology|May 25, 2023
<i>QPOLE</i>: A Quick, Simple, and Cheap Alternative for <i>POLE</i> Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain ReactionAnne Sophie V M Van den Heerik, Natalja T Ter Haar, Lisa Vermij, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 1